EVALUATION OF BETA-ADRENOBLOCKERS TREATMENT IN CARDIOVASCULAR DISEASES COMORBID WITH DIABETES IN OUTPATIENT SETTING

2 FSBEIHEI.P. PavlovRyazanskyStateMedicalUniversity. Ryazan,Russia

Aim. To evaluate the practice of beta-blockers (BB) usage in cardiovascular disease (CVD) patients with diabetes (DM) in two outpatient registries.

Material and methods. Registry PROFILE is the patients (n=1531) with CVD, visited specialized cardiological department of medical research center of Moscow during the period 2011-2015, and registry RECVAZA — patients (n=3690), visited 3 city polyclinics in Ryazan city in 2012-2013.
Number of DM patients is 221 (14,4%) in PROFILE and 699 (18,9%) in RECVAZA.

Results. In the RECVAZA, the rate of BB prescription was almost the same in CVD and DM; in PROFILE there was significantly more frequent prescription of BB, especially after myocardial infarction (86,4%) and in chronic heart failure (72,6%). In both registries bisoprolol was in use most commonly: 61,8% in PROFILE and 75,4% in RECVAZA. Among DM patients, not taking BB, in PROFILE registry there were additional contraindications: chronic obstructive pulmonary disease and asthma, than in RECVAZA.

Conclusion. Clinicians of the specialized cardiological department, comparing to clinicians in local outpatient institutions more actively prescribed BB to DM patients, especially in the cases when this could improve long-term outcomes of the disease. This matches with recent clinical guidelines.

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37 (27): 2129-200. DOI: 10.1093/eurheartj/ehw128.

2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2017; (October): 1-66. DOI: 10.1093/eurheartj/ehx393.

3. Uk JM, Uk HD, Poland MT, et al. Expert consensus document on β-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25 (15): 1341-62. DOI: 10.1016/j.ehj.2004.06.002.

4. Opie LH, Gersh BJ. Drug for the heart 8th edition. Cardiol Pharmacol 2013. DOI: 10.1017/CBO9781107415324.004.

5. Carella AM, Antonucci G, Conte M, et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 2010; 6 (4): 215-21. DOI: 10.2174/157339910791658844.

6. Boytsov SA, Chuchalin AG. Prevention of chronic non-infectious diseases. Guidelines 2013. Moscow. National Foundation for the Support of Preventive Medicine “PROFMEDFORUM” 2013; 40 p. (in Russ.) Бойцов С. А., Чучалин А. Г. Профилактика хронических неинфекционных заболеваний. Рекомендации 2013. Москва. Национальный фонд поддержки профилактической медицины “ПРОФМЕДФОРУМ” 2013; 40 с.

7. Dézsi CA, Szentes V. The Real Role of β-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs 2017; 17 (5): 361-73. DOI: 10.1007/s40256-017-0221-8.

8. Martsevich SYu, Zakharova NA, Kutishenko NP, et al. Practice of prescribing beta- blockers and its compliance with clinical guidelines according to two registers of cardiovascular diseases. Rational Pharmacotherapy in Cardiology 2016; 3: 260-4. (in Russ.) Марцевич С. Ю., Захарова Н. А., Кутишенко Н. П., et al. Изучение практики назначения бета-адреноблокаторов и ее соответсвия современным клиническим рекомендациям в рамках двух амбулаторных регистров сердечно-сосудис тых заболеваний. Рациональная фармакотерапия в кардиологии 2016; 12 (3): 260-4. DOI: 10.20996/1819-6446-2016-12-3-260-264

9. Boytsov SA, Yakushin SS, Martsevich SYu, et al. Outpatient register of cardiovascular diseases in the ryazan region (RECVASA): Principal tasks, experience of development and first results. Ration Pharmacother Cardiol 2013; 9 (1): 4-14. (in Russ.) Бойцов С. А., Якушин С. С., Марцевич С. Ю. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. Рациональная фармако-терапия в кардиологии 2013; 9 (1): 4-14.

10. Dornhorst A, Powell S, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type ii diabetics without alteration of insulin secretion. Lancet. 1985; 325 (8421): 123-6. DOI: 10.1016/S0140-6736(85)91900-2.

11. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34 (28): 2159-219. DOI: 10.1093/ eurheartj/eht151.

12. Messerli FH, Bell DSH, Fonseca V, et al. Body Weight Changes with ??-Blocker Use: Results from GEMINI. Am J Med 2007; 120 (7): 610-15. DOI: 10.1016/j. amjmed.2006.10.017.

13. Martsevich SYu, Kutishenko NP. CAMELLIA trial: comparison in therapies based on carvedilol and metoprolol in hypertensive patients with overweight and obesity. Rational Pharmacotherapy in Cardiology 2008; 4 (5): 34-8. (in Russ.) Марцевич С. Ю., Кутишенко Н. П. Исследование камелия: cравнение терапии, основанной на карведилоле и метопрололе, у больных артериальной гиперто-нией и избыточной массой тела/ожирением. Рациональная фармакотерапия в кардиологии 2008; 4 (5): 34-8.

14. Martsevich SYu, Tolpygina SN, Volkova EG, et al. Comparison of the influence of long-term treatment based on carvedilol or bisoprolol on metabolic parameters in hypertensive patients with overweight or obesity results of the randomized open-label parallel-groups stepped trial cabriolet (part I). Rational Pharmacotherapy in Cardiology 2012; 4: 488-99. (in Russ.) Марцевич С. Ю., Толпыгина С. Н., Волкова Э. Г. и др. Сравнение влияния длительной терапии, основанной на карведилоле или бисопрололе, на метаболические параметры у боль-ных артериальной гипертонией и избыточной массой тела или ожирением. Результаты рандомизированного открытого параллельного ступенчатого иссл. Рациональная фармакотерапия в кардиологии 2012; 8 (4): 488-99.